CompanyATHE PRNAFNasdaq, OTCMelbourne

Alterity Therapeutics

Alterity Therapeutics develops ATH434, a small molecule therapy for multiple system atrophy and related Parkinsonian disorders.

SEC EDGAR ClinicalTrials.gov alteritytx.com

6-KSep 25Latest SEC filing

Aug 28Latest story

August 2026

Alterity Therapeutics discloses governance practices in August 2026 filing

Aug 28Regulatory decisionAlterity Therapeutics

July 2026

Alterity says FDA confirmed registrational path for ATH434 in MSA

Jul 30Regulatory decisionAlterity Therapeutics ATH434

Alterity registers open-label extension for ATH434 in French MSA patients

Jul 28Trial updateAlterity Therapeutics ATH434

Alterity Therapeutics CEO to attend BTIG Biotechnology Conference 2026

Jul 21PeopleAlterity Therapeutics

Alterity gets FDA meeting minutes backing Phase 3 path for ATH434 in MSA

Jul 7Regulatory decisionAlterity Therapeutics ATH434